Advances in Yeast Glucan Particles for Oral Drug Delivery

In recent years, yeast glucan particles (YGPs) have garnered significant attention as novel oral drug delivery carriers, owing to their superior biocompatibility, specific targeting capabilities, and intrinsic immunomodulatory properties. The yeast cell wall is primarily composed of β-glucan and mannan, with minor amounts of proteins and lipids. Among these, β-1,3-glucan serves as the pivotal functional component. It not only provides a physical barrier protecting payloads from gastric acidity and enzymatic degradation but also functions as a targeting ligand. By specifically binding to M cells in Peyer’s patches and Dectin-1 receptors on macrophages and dendritic cells, β-1,3-glucan facilitates precise drug delivery to gut-associated lymphoid tissue (GALT) or macrophage-rich inflammatory sites. Consequently, β-1,3-glucan-based YGPs demonstrate immense potential in oral targeted delivery systems for macrophage-associated pathologies. However, native YGPs, constrained by their inherent porous architecture and relatively simple physicochemical properties, often fall short of meeting the complex requirements for precise encapsulation, controlled release, and multifunctionality. To address these limitations, current research is actively exploring the functionalization of YGPs with various composite materials to engineer advanced delivery platforms. This review introduces the composition, structural characteristics, and fabrication methodologies of YGPs, alongside their specific merits and limitations in oral drug delivery. Furthermore, it critically analyzes strategies for modifying YGPs with composite materials to overcome delivery barriers. Finally, the review discusses their therapeutic applications across various diseases and outlines future developmental trends.